Stromal tissue derived from adult bone marrow (BM) contains clonogenic progenitor cells (CFU-F), some of which are considered to be multi-potent MSCs, capable of differentiating into a range of mesenchymal cell lineages. 1 Current methods for the isolation of BM-MSCs rely upon the rapid adhesion of the stromal progenitor populations to tissue culture plastic and their subsequent rapid proliferation in vitro, 2 resulting, however, in a heterogeneous starting population of adherent BM cells. A significant proportion of the latter represent adherent monocytic cells, the major cause of false-positive results in studies investigating the origin of BM-stromal cells following SCT. 3 In addition, BM-MNCs from patients post allogeneic transplantation show a significant impairment in the ability to generate confluent SC-layers in long-term Dexter-type cultures preventing molecular assessment of chimerism. 4, 5 Therefore, studies based on these methods are limited by monocyte-macrophage contamination and defective SC growth.
Recent studies have demonstrated that positive selection using a commercialized anti-endoglin (CD105) antibody enables to obtain homogenous SC-cultures to be obtained without contamination with hematopoietic-derived cells. 6 We hypothesized that cultures initiated with immunomagnetically isolated BM-CD105 þ cells, a cell fraction enriched in mesenchymal progenitor cells (MPC), from patients after hematopoietic SCT would efficiently generate SC-layers without cells of hematopoietic origin, suitable for accurate SC-chimerism analysis. We chose to use the anti-CD105 monoclonal antibody for MPC enrichment for two reasons: First, it was the only commercially available antibody for direct immunomagnetic positive selection of MPCs and secondly preliminary work in our lab has shown that a sample of 4-5 ml BM would be enough for obtaining SC-layers in cultures supplemented with bFGF.
We obtained 4-6 ml BM samples from 12 patients 1-24 months post matched sibling allogeneic SC. Five of these patients had suffered from b-thalassemia and the rest from malignant hematological diseases. The isolated BM-CD105 þ cells were cultured under LTBMC conditions with the addition of bFGF. We also cultured the unbound CD105
À cells under the same conditions. Enough stromal progenitor cell growth for molecular analysis occurred in all samples studied. In most samples there were no detectable mesenchymal cells in cultures initiated with CD105 À cells. We detected the cell surface molecules expressed by cultured cells at the time of the first passage by immunohistochemical staining and flow cytometry. Flow cytometry showed that cultured cells did not express certain hematopoietic and endothelial markers, such as CD45, CD31, CD34, CD62L, CD64, and CD133. On the other hand, cultured cells were found positive for CD105, CD29, CD44, class I HLA, Vimentin, and SMA ( Figure 1) . Therefore, the isolated BM-CD105 þ cells generated confluent marrow stromal layers in 10-14 days without hematopoietic cell contamination in all samples cultured.
Chimerism was analyzed both in unfractionated BM and cultured cells (Figure 2) . Preliminary experiments to standardize the PCR assays demonstrated a level of sensitivity of 1%. DNA was extracted at various time points of the culture and the origin of the cells was determined using PCR-STRs. At the time of the study all patients displayed full donor hematopoeisis. For two of the patients post sex-mismatched transplant, primers for the Y-linked locus were used, whereas for the remaining 10 patients, other STR loci were used in order to discriminate between donor and recipient. STR-PCR analysis showed that cultured cells from all patients originated exclusively from the BM of recipients, even if they were genotyped shortly after the time of the first passage.
In contrast to other chimerism studies using SCs derived in vitro from BM-MNCs, 4,5 cultured CD105 þ cells from all of our patients generated a confluent stromal layer and were able to expand as efficiently as BM-SCs from normal donors. The growth advantage of SCs in cultures initiated with enriched CD105 þ -MPCs might be attributed to the elimination of cells that possibly suppress SC-proliferation and/or the use of bFGF that has been shown to correct the proliferative defect of these cells after HSCT. 7 Previous chimerism studies on SCs have pointed out that extensive culture (more than three passages) of SCs is crucial for avoiding macrophage-contamination especially when a limited engraftment of MPCs is suspected. 4, 5 Our data show clearly that the BM-cell population enriched in CD105 þ cells gives rise to pure SCs soon after the first passage forming a confluent cell layer with a fibroblastic morphology. Detailed cytometric analysis and immunohistochemical staining of cells derived from cultures before second passage excluded contamination of cultures with hematopoietic cells. Thus, we were able to securely perform molecular assessment of chimerism at this early time point (10-14 days) in all samples examined.
As in the majority of published studies, in our study stromal cells (SC) were exclusively of host origin in all cases, independent of the underlying disease or time post transplant. In two recent studies a contribution of donor MPCS to BM-stroma occurring later in the post-transplant period in some patients with multiple myeloma and aplastic anemia was demonstrated. 8, 9 Since there are conflicting data at least for aplastic anemia, 10 we suggest that a method ensuring complete depletion of cells of hematopoietic origin and optimal SC-growth must be chosen for studying MPC-engraftment after SCT in patients with diseases damaging BM-stroma.
In summary, the use of BM-CD105 þ cells seems to be more efficient than the usual use of BM-MNCs in obtaining pure confluent SC-layers, enabling with high confidence the study of SC-chimerism in patients after SCT and/or MPCT. 
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